BGN

Across TCGA pan-cancer cohorts, BGN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BGN data layer compared with 18 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BGN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BGN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, LSCC, and COAD are the cancer types where BGN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.372	0.865	.004	26	view →
LSCC	DFS	Median	II,III,IV	0.828	1.000	.002	18	view →
COAD	DFS	Median	II,III,IV	0.878	1.000	.017	12	view →
GBM	OS	Tertile	All	0.247	0.503	.014	4	view →
PDAC	DFS	Quartile	II,III,IV	0.883	0.666	.021	3	view →
CCRCC	OS	Tertile	All	1.000	0.723	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BGN–LUAD (OS)

Open the LUAD breakdown →